Regeneron stock heads into the open after a 1.8 percent drop
Published on 09/11/2026 at 08:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron stock closed at USD 793.26 on Nasdaq on September 10, 2026, losing 1.78 percent from the prior session per Nasdaq data at Yahoo Finance. The move left the shares below the USD 800 mark while broader biotech and growth benchmarks were comparatively steadier, underscoring a bout of stock-specific pressure.
September 10, 2026 in numbers
Regeneron Pharmaceuticals Inc. (ISIN US75886F1075, Nasdaq: REGN) traded in a session range that saw the price oscillate around the low USD 800s before settling at USD 793.26 on September 10, 2026, according to Nasdaq summary data at MarketBeat. That close represented a 1.78 percent decline and came after the stock had previously been supported by strong second-quarter 2026 results earlier in the week, when it finished at USD 810.31 on September 8, 2026 following an earnings beat highlighted by earnings per share of USD 14.29 as reported by Ad-hoc-news. In valuation terms, the recent pullback leaves the shares a few percentage points below the average analyst price target of USD 800.36 cited by MarketBeat, even as the stock remains well above the lows associated with earlier clinical trial setbacks.
Analyst activity also framed recent trading. On September 10, 2026, HSBC reiterated a buy stance on Regeneron and raised its price target to USD 920, according to a headline alert from Benzinga. A follow-up note summarized by MarketBeat emphasized that shares opened above USD 800 on the same day, highlighting that the subsequent close near USD 793.26 left meaningful upside versus that revised target.
Class action headlines and data-watch today
Today, September 11, 2026, investor litigation deadlines remain part of the backdrop for Regeneron. Several law firms have reiterated that investors who bought Regeneron shares between August 1, 2025 and May 15, 2026 face a September 14, 2026 lead-plaintiff deadline in a securities class action tied to the market reaction after a failed clinical trial, as outlined by PR Newswire via Barchart. Additional reminders of the same deadline have been issued by firms including Pomerantz and Bernstein Liebhard, adding legal overhang but without a scheduled corporate event for today in the investor-relations calendar. Against that backdrop, trading into the open is likely to be shaped by broader biotech sentiment, ongoing digestion of the recent HSBC price-target increase, and any fresh headlines around the class action as the September 14, 2026 milestone approaches.
